Simplex Trading’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-67,900
| Closed | -$1.64M | – | 10420 |
|
|
2023
Q1 | $1.64M | Sell |
67,900
-61,100
| -47% | -$767K | ﹤0.01% | 2121 |
|
|
2022
Q4 | $1.36M | Buy |
129,000
+54,000
| +72% | +$436K | ﹤0.01% | 2180 |
|
|
2022
Q3 | $337K | Buy |
75,000
+35,500
| +90% | +$162K | ﹤0.01% | 3932 |
|
|
2022
Q2 | $158K | Sell |
39,500
-27,600
| -41% | -$131K | ﹤0.01% | 4923 |
|
|
2022
Q1 | $491K | Buy |
67,100
+2,700
| +4% | +$16.1K | ﹤0.01% | 3866 |
|
|
2021
Q4 | $361K | Sell |
64,400
-21,100
| -25% | -$134K | ﹤0.01% | 4284 |
|
|
2021
Q3 | $712K | Buy |
85,500
+20,600
| +32% | +$132K | ﹤0.01% | 3576 |
|
|
2021
Q2 | $547K | Buy |
64,900
+63,916
| +6,496% | +$516K | ﹤0.01% | 4016 |
|
|
2021
Q1 | $1.03M | Buy |
984
+912
| +1,267% | +$12.8K | ﹤0.01% | 2356 |
|
|
2020
Q4 | $121K | Sell |
72
-55
| -43% | -$824 | ﹤0.01% | 5253 |
|
|
2020
Q3 | $162K | Sell |
127
-163
| -56% | -$2.06K | ﹤0.01% | 4360 |
|
|
2020
Q2 | $409K | Sell |
290
-8
| -3% | -$101 | ﹤0.01% | 3158 |
|
|
2020
Q1 | $274K | Sell |
298
-570
| -66% | -$7.35K | ﹤0.01% | 3238 |
|
|
2019
Q4 | $1.29M | Buy |
+868
| New | +$7.74K | ﹤0.01% | 1853 |
|
Other funds holding PRVB
Simplex Trading's PRVB Position: Q2 2023 in Review
Simplex Trading sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 47,345 shares — an estimated $1.14M sold.
Simplex Trading first reported a position in PRVB in Q3 2019 and held it in 14 quarters. The position peaked at $1.14M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Simplex Trading reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Simplex Trading sold 47,345 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.14M.
- Simplex Trading first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 14 quarters.
- Simplex Trading's Provention Bio, Inc. Common Stock position peaked at $1.14M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.